Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
HLA Evolutionary divergence
acute myeloid leukemia
graft-versus-host disease (GVHD)
graft-versus-leukemia (GVL)
hematopoietic (stem) cell transplantation (HCT)
immune reconstitution
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
12
2021
accepted:
15
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Class I Human Leukocyte Antigen (HLA) evolutionary divergence (HED) is a metric which reflects immunopeptidome diversity and has been associated with immune checkpoint inhibitor responses in solid tumors. Its impact and interest in allogeneic hematopoietic stem cell transplantation (HCT) have not yet been thoroughly studied. This study analyzed the clinical and immune impact of class I and II HED in 492 acute myeloid leukemia (AML) recipients undergoing HCT. The overall cohort was divided into a training (n=338) and a testing (n=132) set. Univariate cox screening found a positive impact of a high class I HED and a negative impact of a high class II HED on both disease-free (DFS) and overall survival (OS). These results were combined in a unique marker, class I/class II HED ratio, and assessed in the testing cohort. The final multivariate cox model confirmed the positive impact of a high
Identifiants
pubmed: 35309346
doi: 10.3389/fimmu.2022.841470
pmc: PMC8931406
doi:
Substances chimiques
HLA Antigens
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841470Informations de copyright
Copyright © 2022 Daull, Dubois, Labussière-Wallet, Venet, Barraco, Ducastelle-Lepretre, Larcher, Balsat, Gilis, Fossard, Ghesquières, Heiblig, Ader and Alcazer.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Evolution. 2011 Aug;65(8):2380-90
pubmed: 21790583
Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7
pubmed: 25459643
Bone Marrow Transplant. 2020 Aug;55(8):1658-1661
pubmed: 32054997
Blood. 2006 Sep 15;108(6):2106-13
pubmed: 16757687
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
Haematologica. 2016 Jun;101(6):680-7
pubmed: 27252513
Mol Biol Evol. 2018 Sep 1;35(9):2145-2158
pubmed: 29893875
Science. 1974 Sep 6;185(4154):862-4
pubmed: 4843792
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Nat Rev Immunol. 2005 Mar;5(3):201-14
pubmed: 15719024
Front Immunol. 2017 Jun 07;8:496
pubmed: 28638379
J Exp Med. 1995 Jun 1;181(6):2085-95
pubmed: 7760000
Genetics. 1993 Mar;133(3):669-80
pubmed: 8454208
Blood. 2007 Dec 15;110(13):4576-83
pubmed: 17785583
Blood. 2007 Feb 15;109(4):1355-62
pubmed: 17008540
Blood Rev. 2013 Jan;27(1):1-12
pubmed: 23182478
Nucleic Acids Res. 2015 Jan;43(Database issue):D423-31
pubmed: 25414341
Br J Haematol. 2016 Apr;173(2):190-205
pubmed: 27019012
Front Immunol. 2021 Jan 25;11:614976
pubmed: 33569061
Blood. 2017 Feb 9;129(6):791-798
pubmed: 27872059
Immunogenetics. 2016 Jul;68(6-7):401-416
pubmed: 27233953
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4
pubmed: 8265660
Br J Haematol. 2001 Mar;112(4):988-94
pubmed: 11298597
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
J Mol Evol. 1997 Dec;45(6):599-609
pubmed: 9419237
Science. 1996 Apr 5;272(5258):67-74
pubmed: 8600539
HLA. 2018 Nov;92(5):271-278
pubmed: 30232844
Bone Marrow Transplant. 2010 Jan;45(1):177-80
pubmed: 19430502
Trends Ecol Evol. 1990 Jun;5(6):181-7
pubmed: 21232350
Ann Intern Med. 2021 Oct;174(10):1385-1394
pubmed: 34424731
PLoS Genet. 2017 Jun 26;13(6):e1006862
pubmed: 28650991
Transfus Med Hemother. 2019 Oct;46(5):326-336
pubmed: 31832058
Blood. 1990 Feb 1;75(3):555-62
pubmed: 2297567
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650450
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585